Medicxi Announces $40m investment in D3 Bio

Medicxi China United Kingdom Jersey California

Investment will support development of a differentiated pipeline in oncologyMost advanced asset is D3S-001 with potential to be a best-in-class KRAS G12C inhibitorData on lead asset D3S-001 to be presented at AACR on 8 April 2024View original content:https://www.prnewswire.co.uk/news-releases/medicxi-announces-40m-investment-in-d3-bio-302109868.html